Description

Colomicin (sodium colistimethate) powder for solution for injections 2000000 IU №10 vial

Ingredients:

Colistimethate sodium is the active ingredient in Colomicin. Each vial contains 2000000 IU of colistimethate sodium.

Dosage:

The recommended dosage of Colomicin is determined by the healthcare provider based on the patient’s condition. It is usually administered by intravenous injection.

Indications:

Colomicin is indicated for the treatment of infections caused by susceptible strains of bacteria.

Contraindications:

Do not use Colomicin if the patient is allergic to colistimethate sodium or any other ingredients in the product.

Directions:

Follow the instructions provided by the healthcare provider for the proper administration of Colomicin. It is important to complete the full course of treatment.

Scientific Evidence:

Colistimethate sodium has been extensively studied for its efficacy in treating various bacterial infections. Research studies have shown that Colomicin is effective against multidrug-resistant gram-negative bacteria, making it a valuable treatment option in clinical practice.

Additional Information:

In addition to its antibacterial properties, colistimethate sodium has been found to have anti-inflammatory effects, further contributing to its therapeutic benefits in certain infections. Clinical trials have demonstrated the safety and efficacy of Colomicin in patients with severe bacterial infections.

Overall, Colomicin (sodium colistimethate) powder for solution for injections 2000000 IU №10 vial is a potent antibiotic with a well-established role in the management of challenging bacterial infections. Its pharmacological action involves disrupting the bacterial cell membrane, leading to cell death. Compared to other antibiotics, Colomicin stands out for its effectiveness against multidrug-resistant bacteria, providing a crucial treatment option in clinical settings.

References:
1. Li J, Nation RL, Milne RW, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589-601.
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333-1341.